Adkison K - Search Results

1

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.

Boffito M, Waters L, Cahn P, Paredes R, Koteff J, Van Wyk J, Vincent T, Demarest J, Adkison K, Quercia R. Boffito M, et al. Among authors: adkison k. AIDS Res Hum Retroviruses. 2020 Jan;36(1):13-18. doi: 10.1089/AID.2019.0171. Epub 2019 Oct 21. AIDS Res Hum Retroviruses. 2020. PMID: 31507204 Free PMC article. Review.

2

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.

Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S. Lalezari J, et al. Among authors: adkison k. AIDS. 2005 Sep 23;19(14):1443-8. doi: 10.1097/01.aids.0000183633.06580.8a. AIDS. 2005. PMID: 16135896 Clinical Trial.

3

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.

Mehta R, Wolstenholme A, Di Lullo K, Fu C, Joshi S, Crauwels H, Givens N, Vanveggel S, Wynne B, Adkison K. Mehta R, et al. Among authors: adkison k. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00748-18. doi: 10.1128/AAC.00748-18. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 29987139 Free PMC article. Clinical Trial.

4

Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.

Singh RP, Adkison K, Wolstenholme A, Hopking J, Wynne B. Singh RP, et al. Among authors: adkison k. Clin Pharmacol Drug Dev. 2021 Sep;10(9):985-993. doi: 10.1002/cpdd.996. Epub 2021 Jul 15. Clin Pharmacol Drug Dev. 2021. PMID: 34265164 Free PMC article. Clinical Trial.

5

In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.

Demarest JF, Sparks SS, Schell K, Shibayama S, McDanal CB, Fang L, Adkison KK, Shachoy-Clark A, Piscitelli SC. Demarest JF, et al. Among authors: adkison kk. J Clin Pharmacol. 2008 Oct;48(10):1179-88. doi: 10.1177/0091270008322178. Epub 2008 Aug 1. J Clin Pharmacol. 2008. PMID: 18676693 Clinical Trial.

6

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.

Singh RP, Adkison KK, Baker M, Parasrampuria R, Wolstenholme A, Davies M, Sewell N, Brothers C, Buchanan AM. Singh RP, et al. Among authors: adkison kk. Pediatr Infect Dis J. 2022 Mar 1;41(3):230-237. doi: 10.1097/INF.0000000000003366. Pediatr Infect Dis J. 2022. PMID: 34817414 Clinical Trial.

7

Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.

Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K. Aboud M, et al. Among authors: adkison k. Lancet HIV. 2019 Sep;6(9):e576-e587. doi: 10.1016/S2352-3018(19)30149-3. Epub 2019 Jul 12. Lancet HIV. 2019. PMID: 31307948 Clinical Trial.

8

Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.

Dumitrescu TP, Peddiraju K, Fu C, Bakshi K, Yu S, Zhang Z, Tenorio AR, Spancake C, Joshi S, Wolstenholme A, Adkison K. Dumitrescu TP, et al. Among authors: adkison k. Clin Pharmacol Drug Dev. 2020 Feb;9(2):189-202. doi: 10.1002/cpdd.740. Epub 2019 Nov 14. Clin Pharmacol Drug Dev. 2020. PMID: 31724343 Free PMC article. Clinical Trial.

9

Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.

Adkison K, Wolstenholme A, Lou Y, Zhang Z, Eld A, Perger T, Vangerow H, Hayward K, Shaefer M, McCoig C. Adkison K, et al. Clin Pharmacol Ther. 2018 Mar;103(3):402-408. doi: 10.1002/cpt.943. Epub 2017 Dec 11. Clin Pharmacol Ther. 2018. PMID: 29150845 Free PMC article. Clinical Trial.

10

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.

Paediatric European Network for Treatment of AIDS (PENTA). Paediatric European Network for Treatment of AIDS (PENTA). Antivir Ther. 2010;15(3):297-305. doi: 10.3851/IMP1532. Antivir Ther. 2010. PMID: 20516550 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters